Kamada Ltd - רווח נקי למניה אחת בשנים עשר החודשים האחרונים KMDA

As a biopharmaceutical business, Kamada Ltd. (KMDA) strictly adheres to ESG principles by implementing water purification systems and safe waste processing. Financial stability relies on a synthesis of plasma protein production and the resale of foreign brands. This daily price action reflects a monetary market trend for EPS TTM of 21.30, while profit growth remains constrained by the cost of donor raw materials despite stable sales of therapeutic products.
Kamada Ltd. - פילוחים אנליטיים ומדדי מפתח (KMDA)

This indicator captures the net profit per share dynamics over the last twelve months relative to the previous year. By analyzing the EPS YoY TTM growth efficiency metric, an investor assesses the real scaling speed of the business capitalization. The monopoly status of Kamada Ltd. (KMDA) in the plasma-replacement drug segment allows the company to transform the high cost of injections into stable profit growth. The steady trajectory of the curve confirms the issuer's solvency and justifies the premium valuation of the assets.